10 AI Stocks Worth Buying Right Now

Motley Fool recommends a diversified basket of 10 smaller, focused AI plays across voice AI, warehouse robotics, enterprise automation, drug discovery, fintech and defense as higher-upside complements to richly valued megacaps. Notable specifics include Upstart reporting Q3 2025 revenue up 71% year-over-year and BigBear.ai carrying a $376 million backlog, while C3.ai is framed as a turnaround under new CEO leadership (late 2025); Absci and Recursion are highlighted for AI-native drug design. The piece argues that owning exposure across multiple AI verticals improves the odds of capturing outsized returns and discloses Motley Fool's positions and recommendations in several listed names.

Analysis

Market structure: The near-term winners are focused AI application vendors (SYM, PATH, PLTR, UPST, RXRX, ABSI) that sell measurable cost savings or revenue lifts — they can expand share versus legacy incumbents whose valuations already price AI growth (NVDA, MSFT). Pricing power will bifurcate: platform providers keep rent (GPUs/cloud), while vertical specialists compete on ROI and service margins; expect multi-year consolidation with 3–5 clear leaders per vertical. Supply/demand signals: sustained demand for GPUs and datacenter capacity supports Nvidia/semi cycle risk; robotics pushes capital equipment demand and raises energy consumption in local grids; FX/USD strength can shave 3–7% off offshore revenue in next 12 months if dollar stays elevated.

Risk assessment: Tail risks include regulatory AI constraints, US export controls on chips, DoD contract shifts, and biotech trial failures (ABSI/RXRX) — any can trigger >30% drawdowns in small caps. Time-framing: days–weeks driven by sentiment/earnings, months by contract rollouts and FY budgets, years by consolidation and platform dominance. Hidden dependencies: heavy reliance on Nvidia GPUs, cloud credits, and large enterprise procurement cycles; losing one major client can cut revenue visibility by >20%. Key catalysts: enterprise procurement wins, FDA readouts, DoD awards, and Nvidia supply shifts within 30–180 days.

Trade implications: Direct plays: overweight capital-efficient automation (SYM 2–4% position) and software leaders (PATH, PLTR 1–3% each) using cash or 6–12 month call spreads to cap premium decay; prefer entry on >10–15% pullbacks or post-contract announcements. Relative trades: pair long PATH vs short speculative AI-app names (e.g., AI/C3.ai) to exploit execution premium; use defined-risk 3–6 month put spreads on hype names that run >30%. Macro hedges: trim 5–10% of NVDA/MSFT hardware exposure and buy 3–6 month protective puts if NVDA rallies >20% in 30 days.

Contrarian angles: Consensus underestimates execution and capital intensity — many small AI names are priced for flawless commercialization; this favors selective longs with clear KPIs and shorts on headline-chasing entrants. Historical parallel: 1990s internet — platforms captured most profit while many application-layer winners failed; expect similar winner-take-most dynamics over 2–5 years. Unintended consequence: tighter regulation or hardware bottlenecks will advantage large incumbents with compliance/legal budgets and long-term supply contracts, reversing small-cap outperformance quickly.

Key Decisions for Investors

• Establish a 2–4% long position in Symbotic (SYM) within 1–3 months, scaling in on any pullback ≥10%; target 12–24 month upside of +80–120%, set a stop-loss at −25% from cost to limit execution risk.
• Initiate 1–3% positions in UiPath (PATH) and Palantir (PLTR) funded by trimming 5–10% of NVDA/MSFT exposure; use 9–12 month call spreads (buy ATM, sell 25–35% OTM) to gain asymmetric upside while capping premium risk.
• Implement defined-risk bearish trades on hype/sentiment names: buy 3–6 month put spreads on C3.ai (AI) or SoundHound (SOUN) if either rallies >30% from current levels, sizing each spread to 0.5–1.5% portfolio risk.
• Defer or limit biotech AI allocations (ABSI, RXRX) to ≤1% each until key catalysts: FDA/clinical readouts or partner licensing decisions occur within 6–12 months; if positive catalysts arrive, convert to 1–2% long positions and use 12-month LEAP calls to leverage.